Lightbridge Corporation

As of June 30, 2026, Lightbridge held approximately $237.5 million in cash and cash equivalents, versus approximately $201.9 million at December 31, 2025. For the first half of 2026, net loss was $12.1 million versus $8.3 million in the first half of 2025. R&D expenses were $7.3 million for the six months ended June 30, 2026, up from $3.3 million a year earlier, and G&A expenses were $8 million versus $6 million. Total other income was $3.2 million, compared with $1 million last year, driven by interest income. The company did not provide next-quarter or full-year revenue or EPS guidance on the call; it said its cash position is sufficient to fund operations for an extended period and that it will continue evaluating strategic partnerships, government grants, contracts, and additional capital market transactions as needed.

Seth Grae framed the quarter as an important execution period for Lightbridge’s fuel commercialization effort. He emphasized the ATR sample removal, the Studsvik software integration, and the Centrus HALEU MOU as evidence that the company is advancing both technical validation and the supply chain needed for deployment. His tone was optimistic and policy-oriented, stressing that government initiatives and utility input are increasingly aligned with Lightbridge’s long-term plan.

Lawrence Goldman focused on balance sheet strength, saying cash and cash equivalents were approximately $237.5 million at June 30, 2026, up from approximately $201.9 million at year-end 2025. He said the company used approximately $8.3 million in operations in the first half of 2020 and generated approximately $43.9 million in net cash from financing, including $44.4 million in net proceeds from ATM sales of about 3.8 million shares. He also said capital allocation remains disciplined and milestone-driven, with spending directed toward fuel development, radiation testing, post-irradiation examination, computational infrastructure, and safety analysis.

There was no analyst Q&A on the call, and Seth Grae explicitly said no questions had been submitted. As a result, no follow-up concerns or management clarifications were aired beyond the prepared remarks. The main open topics left for later discussion were the timing of post-irradiation examination, the nonbinding HALEU MOU with Centrus, and future funding options.